Hold on to your huaraches: as part of its 65th anniversary, Lilly Pulitzer is dipping a pastel-painted toe into the world of ...

The designer at New York–based Crafted Interiors shares a bird’s-eye view of his favorite swatches, samples and more.

Expect to see these prints everywhere next year. Bring on the prints in 2025! If you love a bit of pattern play, keep reading ...

Elevate your golf game with this Lilly Pulitzer ... a fun pink gingham print for effortless style on the course. Add a touch of coastal charm to your style with this breezy blue button-down ...

Eli Lilly reported third-quarter results before the market opened on Wednesday. Management missed Wall Street estimates and lowered earnings guidance for 2024. Sales of Zepbound and Mounjaro ...

Please go ahead. Thank you, Paul, and good morning, everybody. Thanks for joining us for Eli Lilly and Company's Q3 2024 earnings call. I'm Joe Fletcher, Senior Vice President of Investor Relations.

AJ Mast / Bloomberg via Getty Images Eli Lilly (LLY) shares tumbled 12% at the opening bell Wednesday after its third-quarter results fell well short of analysts' estimates and it lowered its full ...

AnaptysBio (NASDAQ:ANAB), which is advancing an arthritis therapy similar to Eli Lilly's (NYSE:LLY) PD-1 agonist peresolimab, sold off in the premarket on Wednesday after the Indiana-based pharma ...

Eli Lilly lowered its 2024 adjusted EPS guidance to $13.02-$13.52 versus prior guidance of $16.10-$16.60 and consensus of $13.47, driven by the acquired IPR&D charges incurred in Q3.

Eli Lilly reported Q3 revenue and earnings that fell short of analysts' expectations. Mounjaro and Zepbound faced challenges as U.S. wholesalers reduced inventories of the drugs. The bull case for ...

Eli Lilly has dropped (PDF) the lead candidate from its $2.4 billion takeover of Dice Therapeutics, shifting the focus of its oral IL-17 psoriasis program to a follow-up molecule. Lilly kicked DC ...